Alectinib Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Alectinib Hydrochloride |
| DrugBank ID | DB11363 |
| Brand Names (EU) | Alecensa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.97% |
Approved Indication (EMA)
Adjuvant treatment of resected non small cell lung cancer (NSCLC) Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK positive NSCLC at high risk of recurrence (see section 5.1 for selection criteria).Treatment of advanced NSCLCAlecensa as monotherapy is indicated for the first line treatment of adult patients with ALK positive advanced NSCLC.Alecensa as monotherapy is indicated for the treatment of adult patients with A
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | fibromatosis, gingival | 99.97% | DL |
| 2 | fibroma of lung | 99.96% | DL |
| 3 | hamartoma of lung | 99.96% | DL |
| 4 | lung hilum carcinoma | 99.96% | DL |
| 5 | lung benign neoplasm | 99.95% | DL |
| 6 | pulmonary sulcus neoplasm | 99.95% | DL |
| 7 | lung germ cell tumor | 99.95% | DL |
| 8 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | 99.95% | DL |
| 9 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | 99.95% | DL |
| 10 | junctional epidermolysis bullosa | 99.95% | DL |
| 11 | lung cancer | 99.94% | DL |
| 12 | ovarioleukodystrophy | 99.93% | DL |
| 13 | junctional epidermolysis bullosa, non-Herlitz type | 99.93% | DL |
| 14 | dehydratase deficiency | 99.92% | DL |
| 15 | Ewing sarcoma | 99.85% | DL |
| 16 | synovial chondromatosis | 99.01% | DL |
| 17 | orbit sarcoma | 99.01% | DL |
| 18 | giant cell tumor of soft tissue | 98.93% | DL |
| 19 | sarcoma, avian | 98.86% | DL |
| 20 | amyotrohpic lateral sclerosis type 22 | 98.38% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.